Breaking News, Financial News

Financial Report: Alkermes 2Q

Revenues climb 72%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alkermes 2Q Revenues: $124.0 million (+72%) 2Q Loss: $16.7 million (loss of $22.3 million 2Q12)   YTD Revenues: $276.2 million (+106%) YTD Earnings: $5.7 million (loss of $35.5 million YTD12) Comments: Manufacturing and royalty revenues for Risperdal Consta and Invega Sustenna/Xeplion were $50.3 million in the quarter, up 12%, with worldwide end-market sales of $564 million, up 15%. Manufacturing and royalty revenues from Ampyra/Fampyra were $5.0 million, compared to $0.6 million in fiscal ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters